Creating Next Generation ADCs with Industry-Leading DAR Precision, Plasma Stability & Tumor-Selective Linker Payload Activation

Time: 11:30 am

Details:

• Showcasing LCB’s novel next-generation site-specific ADC platform technology
• Demonstrating proprietary cancer-selective linker providing significantly improved therapeutic index
• Highlighting tumor-specific and ultra-potent DNA-damaging crosslinking payload with superior efficacy and reduced toxicity